[Tardive dyskinesia: pergolid, a possible therapeutic option].

Abstract

OBJECTIVE:

There's still no effective treatment established for Tardive Dyskinesia. Aim of the study was to analyse the effect of pergolide, a D1 and D2 receptor agonist with prevalence for presynaptic auto receptors, in oro-facial tardive dyskinesia by means of a double-blind, placebo controlled cross-over study. Low-dose pergolide should activate presynaptic auto receptors, decrease dopamintransmission and reduce tardive dyskinesia.

METHOD:

Assessment of dyskinesia was performed with the computer-assisted technique Digital-Imaging-Processing in addition to the clinical scale AIMS (Abnormal-Involuntary-Movement-Scale). 10 patients with oro-facial dyskinesia were examined for alteration to dyskinesia, psychopathology, vital functions and laborchemical parameter.

RESULTS:

Dyskinesia decreased 25 % for relax and 17 % for task conditions under pergolide treatment. Low-dose pergolide showed no side effects or worsening of the psychopathological state. Results of the Digital-Imaging-Processing correlated significantly with the results of clinical AIMS scale, but the computer-assisted technique gives more detailed information about degree and type of the movement disorder.

CONCLUSION:

Results suggest a therapeutic effect of pergolide in tardive dyskinesia, this has to be verified with a larger study population and longer observation. Assessment of dyskinesia is rater independent and more significant with the computer-assisted technique.

• Authors: Alexander Diehl, Dieter F Braus, Christian Büchel, Bertram Krumm, Rossella Medori, Wagner F Gattaz
• Journal: Psychiatrische Praxis (Psychiatr Prax) Vol. 30 Issue 6 Pg. 333-7 (Sep 2003) ISSN: 0303-4259 [Print] Germany
• Vernacular Title: Tardive Dyskinesien: Pergolid als mögliche therapeutische Option.
• PMID: 12970819 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antipsychotic Agents
• Dopamine Agonists
• Neuroprotective Agents
• Pergolide

Topics

• Adult
• Aged
• Antipsychotic Agents (adverse effects, therapeutic use)
• Cross-Over Studies
• Dopamine Agonists (adverse effects, therapeutic use)
• Double-Blind Method
• Dyskinesia, Drug-Induced (drug therapy, etiology)
• Female
• Humans
• Image Processing, Computer-Assisted
• Male
• Middle Aged
• Neurologic Examination (drug effects)
• Neuroprotective Agents (adverse effects, therapeutic use)
• Pergolide (adverse effects, therapeutic use)
• Pilot Projects
• Schizophrenia (drug therapy)
• Treatment Outcome